Evaluation of compounded bevacizumab prepared for intravitreal injection Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Drug Compounding
  • Drug Packaging

abstract

  • Test results from intravitreal preparations of bevacizumab acquired from compounding pharmacies were negative for microbial contaminants and endotoxin. However, there were significant variations in protein concentration that appear in general to be lower than bevacizumab acquired directly from Genentech. The clinical implications of these variable protein levels remain uncertain.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1001/jamaophthalmol.2014.3591

PubMed ID

  • 25233052

Additional Document Info

start page

  • 32

end page

  • 9

volume

  • 133

number

  • 1